CCDC142: A Potential Drug Target and Biomarker (G84865)

Target Name: CCDC142

NCBI ID: G84865

CCDC142

CCDC142: A Potential Drug Target and Biomarker

Introduction

CDC142 is a protein that is expressed in various tissues of the body and is involved in the development and maintenance of tissues, including brain and spinal cord. The protein is located in the endoplasmic reticulum and is composed of a coiled-coil structure, which gives it its name. In recent years, researchers have become increasingly interested in the potential of drugs that can target CDC142, as it has been suggested to play a role in a variety of diseases, including neurodegenerative disorders and cancer. In this article, we will explore the biology and potential drug targets of CDC142.

The Biology of CDC142

CDC142 is a transmembrane protein that is expressed in a variety of tissues, including brain, spleen, heart, and pancreas. It is primarily localized to the endoplasmic reticulum, where it is involved in the formation and maintenance of the reticulum. CDC142 is composed of a coiled-coil structure that gives it its unique structure and function. The coiled-coil is composed of a series of amino acids that are involved in the formation of a alpha-helices, which are thought to play a role in the stability and localization of the protein.

In addition to its role in the reticulum, CDC142 is also involved in the development and maintenance of tissues in the body. For example, studies have shown that CDC142 is involved in the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. It is also thought to play a role in the development of certain types of cancer, such as neuroendocrine tumors.

The potential drug targets of CDC142

CDC142 has been identified as a potential drug target due to its involvement in the development and maintenance of tissues, as well as its role in the development of certain diseases. In addition, its unique coiled-coil structure has led researchers to consider that it may be a good target for small molecules that can modulate the activity of the protein.

One potential drug that may target CDC142 is currently in clinical trials for the treatment of Alzheimer's disease. The drug, which is being developed by a company called AC Immune, is designed to target the protein using a small molecule called rilastenin. Rilastenin is known for its ability to modulate the activity of the protein and is thought to work by binding to a specific site on the protein.

Another potential drug that may target CDC142 is a small molecule called 尾-amyloid, which is thought to play a role in the development of Alzheimer's disease. 尾-amyloid is a protein that is derived from the amino acids alpha-helices, and is thought to contribute to the formation of neurofibrillary tangles, which are a hallmark of Alzheimer's disease.

The potential use of CDC142 as a biomarker

In addition to its potential as a drug target, CDC142 may also be a useful biomarker for the diagnosis and monitoring of certain diseases. For example, its involvement in the development of neurodegenerative disorders makes it a potential biomarker for Alzheimer's disease. Similarly, its involvement in the development of certain types of cancer makes it a potential biomarker for neuroendocrine tumors.

In addition to its potential as a biomarker, CDC142 may also be used to diagnose certain diseases. For example, its involvement in the development of neurodegenerative disorders makes it a potential biomarker for conditions such as Alzheimer's disease, Parkinson's disease, and Huntington's disease

Protein Name: Coiled-coil Domain Containing 142

The "CCDC142 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC142 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets